LATTICE MEDICAL raises €43 million to transform post-cancer reconstruction
LATTICE MEDICAL raises €43 million to transform post-cancer reconstruction, making it one of the largest medtech deals of the year in France.
Lille, France, October 23, 2025 – LATTICE MEDICAL, a French Medtech company specializing in tissue engineering, announces a Series B fundraising round of €43 million, one of the largest of the year in the French Medtech sector. This major milestone will enable the company to accelerate the clinical development of its MATTISSE medical device, a breakthrough innovation in post-cancer breast reconstruction. This is a strong signal during Pink October, which marks LATTICE MEDICAL’s commitment to supporting women suffering from breast cancer. According to the WHO, there are 2 million new cases of breast cancer worldwide each year, and only 30% of women who have undergone a mastectomy opt for reconstruction. MATTISSE responds to a growing need for more natural, simplified breast reconstruction that does not involve foreign implants in the long term.
This significant fundraising will also enable the development of an innovative industrial tool based in Lille, which will enable the development of the local medical device industry through the integration of 3D printing technologies and resorbable biomaterials in clean rooms. It will enable LATTICE MEDICAL to position itself as a leader in the soft tissue reconstruction market. Thanks to this industrial tool, the company will develop a unique tissue engineering implant manufacturing platform to extend its technology to other therapeutic areas.
This operation is led by the SPI Fund, managed on behalf of the French government as part of France 2030 by Bpifrance, and supported by Blast.Club, Sprim, qualified investors grouped within TIDJEE, as well as long-standing investors EIC Fund, Captech Santé, Nord France Amorçage, and FIRA Nord Est. This fundraising includes non-dilutive financing from banking partners and the two France 2030 programs – M3DINPRINT and LIPOTEC. AVOLTA, the law firm McDermott Will Emery and TIDJEE assisted LATTICE MEDICAL in this strategic transaction.
Acceleration of clinical and industrial development to reindustrialize healthcare in France
The funds will enable the company to:
- Consolidate the clinical development of its MATTISSE and RODIN products, with a view to marketing them in France and internationally;
- Develop its own industrial capacity to produce its medical devices and develop a contract manufacturing offering via Lattice Services;
- and Pursue the company’s mission: to reinvent tissue regeneration solutions to improve the quality of life of cancer patients.
“This fundraising is a real turning point for LATTICE MEDICAL. It allows us to pursue our mission: to reinvent tissue reconstruction after cancer, while building an innovative and industrial French Medtech company that contributes to the health of the region and the quality of life of patients.” Julien PAYEN, CEO of LATTICE MEDICAL.
“The SPI Fund is proud to participate in this fundraising and thus contribute to the emergence of LATTICE MEDICAL as a pioneer in 3D printing of medical devices. Beyond the technological prowess of the MATTISSE and RODIN products, LATTICE MEDICAL offers an innovative and autologous alternative to soft tissue reconstruction solutions, particularly for breast reconstruction, which is a real public health issue. By combining technological innovation, improved quality of life for patients, and job creation in France, the project led by Julien Payen and LATTICE MEDICAL perfectly embodies the ambition of the SPI Fund.” Magalie CLEMENT, Director of SPI Fund of BPIFRANCE
LATTICE MEDICAL: innovative solutions to improve the lives of patients after cancer
LATTICE MEDICAL is an implantable medical device company developing disruptive technology in the field of autologous soft tissue reconstruction. The company uses 3D printing technology and has a dedicated production site. Its work focuses on post-cancer t issue reconstruction, with the aim of offering simplified, less invasive, and more durable alternatives to existing solutions.
Based in Lille and founded in 2017, LATTICE MEDICAL was born out of a collaboration between experts in medicine, surgery, and textile engineering, who came together around a research project aimed at applying the principles of tissue engineering to breast reconstruction and cancer-damaged tissue.
Using unique 3D printing technology, the company develops innovative implants to improve the reconstruction of soft tissue damaged by cancer.
Two flagship medical devices are being developed:
- MATTISSE: a resorbable implant for autologous breast reconstruction after breast cancer, currently undergoing clinical trials in seven centers in France and Spain;
- and RODIN: a matrix for the reconstruction of large subcutaneous tissue defects.
Since 2020, LATTICE MEDICAL has been manufacturing its devices in Wervicq-Sud, controlling the entire manufacturing process and favoring local, short-chain production, thereby contributing to the reindustrialization of the region in the medical field.
